DOI:
10.1055/s-00000077
Seminars in Thrombosis and Hemostasis
LinksClose Window
References
Pollack Jr CV, Reilly PA, Bernstein R , et al.
Design and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatran.
Thromb Haemost 2015;
114 (1) 198-205
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.